07/10/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 7/10/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the WANTAI SARS-CoV-2 Ab Rapid Test. The WANTAI SARS-CoV-2 Ab Rapid Test is authorized for the detection of total antibodies to SARS-CoV-2 inhuman serum, plasma (EDTA, lithium heparin, and sodium citrate) and venous whole blood. (PDF)
No hay comentarios:
Publicar un comentario